Showcasing the Pre-Clinical to Phase I Clinical Development of DS3790 – A Novel CD37 Target & First DXd ADC in Haematology

•  DS3790 is an investigational, potential first-in-class CD37 directed ADC
• Showcasing designs with DXd ADC technology, DS3790 is comprised of a humanized anti-CD37 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (exatecan derivative, DXd) via tetrapeptide-based cleavable linkers

Speakers:

Grzegorz Nowakowski

Senior Vice President, Head of Global Early Development Organization

Daiichi Sankyo